manilatimes5h
Sequential and AMILI Secure Prestigious $1.8M UK-Singapore Collaborative R&D Project to Advance Gut-Skin Microbiome Science
Sequential Skin Ltd, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, are ...
Vietnam Investment Reviev5h
Sequential and AMILI Secure Prestigious $1.8M UK-Singapore Collaborative R&D Project
Sequential Skin Ltd, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, are ...
Azo Sensors11h
AI-Powered Wearable Device Shows Promise in Reducing Nighttime Scratching for Atopic Dermatitis Patients
The AI-driven wearable sensor demonstrates high accuracy in reducing nighttime scratching for atopic dermatitis, improving patient outcomes and sleep quality.
FierceBiotech13h
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
pulmonologyadvisor13h
Early Childhood Stressful Life Events Linked to Increased Eczema Activity
For children with atopic dermatitis, early childhood stressful life events are associated with an increased risk for disease activity.
Rosnilimab shows promise in rheumatoid arthritis trial
SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...
Medscape14h
Pause Immunosuppressants Prior to Patch Testing If Possible
Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...